跳至主要内容
临床试验/CTRI/2022/01/039527
CTRI/2022/01/039527招募中未知

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Patients of ACLF (APASL criteria) - jaundice (serum bilirubin ââ?°Â¥ 5 mg/dL and coagulopathy (INR ââ?°Â¥ 1.5) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis.
  • 2) Age 18-70 yrs
  • 3) Baseline HVPG ââ?°Â¥ 12 mmHg.

排除标准

  • 1) Contraindications to NSBB (heart rate < 65 /min, BP < 110/65 mm Hg, asthma, heart failure),
  • 2) Portal Vein Thrombosis,
  • 3) Hepatocellular carcinoma,
  • 5) HE grades 2-4,
  • 6) NSBB therapy within 5 days,
  • 7) Pregnancy,
  • 8) Lactation,
  • 9) Planned for LT in the next 12 weeks
  • 10) No consent.

研究者

相似试验